Case-Based Review

Diagnosis and Treatment of Migraine

Journal of Clinical Outcomes Management. 2017 November;24(11)

References

1. Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants, J Neurol Sci 2017;372:307–15.

2. Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol 2017;16:76–87.

3. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005;45 Suppl 1:S3–S13.

4. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545–602.

5. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention Headache 2015;55 Suppl 2:103–22.

6. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47:355–63.

7. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study. Lancet 2012;380:2163–96.

8. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646–57.

9. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain in the US workforce. JAMA 2003;290:2443–54.

10. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache 2008;48:553–63.

11. Lipton RB, Serrano D, Holland S, et al. Barriers to the diagnosis and treatment of migraine: Effects of sex, income, and headache features. Headache 2013;53:81–92.

12. Dodick DW, Loder EW, Manack Adams A, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: Results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 2016;56:821–34.

13. Young WB, Park JE, Tian IX, Kempner J. The stigma of migraine. PLoS One 2013;8(1):e54074.

14. Mia M, Ashna S, Audrey H. A migraine management training program for primary care providers: an overview of a survey and pilot study findings, lessons learned, and considerations for further research. Headache 2016;56:725–40.

15. Lipton RB, Amatniek JC, Ferrari MD, Gross M. Migraine: identifying and removing barriers to care. Neurology 1994;44(6 Suppl 4):S63–8.

16. Knapp RD Jr. Reports from the past 2. Headache 1963;3:112–22.

17. Levine M, Wolff HG. Cerebral circulation: afferent impulses from the blood vessels of the pia. Arch Neurol Psychiat 1932;28:140.

18. Amin FM, Asghar MS, Hougaard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross sectional study. Lancet Neurol 2013;12:454–61.

19. Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine—a disorder of sensory processing. Physiol Rev 2017;97:553–622.

20. Goadsby PJ. Pathophysiology of migraine. Ann Indian Acad Neurol 2012;15(Suppl 1):S15–S22.

21. Puledda F, Messina R, Goadsby PJ, et al. An update on migraine: current understanding and future J Neurol 2017 Mar 20.

22. Vinogradova LV. Comparative potency of sensory-induced brainstem activation to trigger spreading depression and seizures in the cortex of awake rats: implications for the pathophysiology of migraine aura. Cephalalgia 2015;35:979–86.

23. Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet 2001;357:1016–7.

24. Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 2016;139:1987–93.

25. Noseda R, Jakubowski M, Kainz V, et al. Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. J Neurosci 2011;31:14204–17.

26. Noseda R, Kainz V, Jakubowski M, et al. A neural mechanism for exacerbation of headache by light. Nat Neurosci 2010;13:239–45.

27. Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol 2017 Mar 20.

28. Coppola G, Di Lorenzo C, Schoenen J, Pierelli F. Habituation and sensitization in primary headaches. J Headache Pain 2013;14:65.

29. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.

30. Yusheng H, Y Li. Typical aura without headache: a case report and review of the literature J Med Case Rep 2015;9:40.

31. Buture A, Khalil M, Ahmed F. Iatrogenic visual aura: a case report and a brief review of the literature Ther Clin Risk Manag 2017;13:643–6.

32. Lipton RB. Tracing transformation: Chronic migraine classification, progression, and epidemiology. Neurology 2009;72:S3–7.

33. Lipton RB. Headache 2011;51;S2:77–83.

34. Scher AI, Stewart WF, et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003;106:81–9.

35. Bigal ME, Lipton RB, Holland PR, Goadsby PJ. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007;68:1851–61.

36. Wolff HG. Stress and disease. Springfield, IL: Charles C. Thomas; 1953.

37. Guidetti V, Galli F, Fabrizi P, et al. Headache and psychiatric comorbidity: clinical aspects and outcome in an 8-year follow-up study. Cephalalgia 1998;18:455–62.

38. Mongini F, Keller R, Deregibus A, et al. Personality traits, depression and migraine in women: a longitudinal study. Cephalalgia 2003;23:186–92.

39. Hung CI, Liu CY, Yang CH, Wang SJ. The impacts of migraine among outpatients with major depressive disorder at a two-year follow-up. PLoS One 2015;10:e0128087.

40. Frishberg BM, Rosenberg JH, Matchar DB, et al. Evidence-based guidelines in the primary care setting: neuroimaging in patients with nonacute headache. St Paul: US Headache Consortium; 2000.

41. Headache Measurement Set 2014 Revised. American Academy of Neurology. Accessed at www.aan.com/uploadedFiles/Website_Library_Assets/Documents/3.Practice_Management/2.Quality_Improvement/1.Quality_Measures/1.All_Measures/2014.

42. Taylor FR. Lifestyle changes, dietary restrictions, and nutraceuticals in migraine prevention. Techn Reg Anesth Pain Manage 2009;13:28–37.

43. Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: A randomized study using relaxation and topiramate as controls. Cephalalgia 2011;14:1428–38.

44. Ahn AH. Why does increased exercise decrease migraine? Curr Pain Headache Rep 2013;17:379.

45. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: The American Headache Society evidence assessment of migraine pharmacotherapies. Headache 2015;55:3–20.

46. Belvis R, Mas N, Aceituno A. Migraine attack treatment : a tailor-made suit, not one size fits all. Recent Pat CNS Drug Discov 2014;9:26–40.

47. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache 2008;48:1157–68.

48. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes Cephalalgia 2004;24:483–90.

49. Silberstein SD, Holland S, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337–45.

50. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial Cephalagia year;30:804–14.

51. Wells RE, Markowitz SY, Baron EP, et al. Identifying the factors underlying discontinuation of triptans. Headache 2014;54:278–89.

52. Holland S, Fanning KM, Serrano D, et al. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. J Neurol Sci 2013;326:10–7.

53. Seng EK, Rains JA, Nicholson RA, Lipton RB. Improving medication adherence in migraine treatment. Curr Pain Headache Rep 2015;19:24.

54. Nicholson RA, Buse DC, Andrasik F, Lipton RB. Nonpharmacologic treatments for migraine and tension-type headache: how to choose and when to use. Curr Treatment Opt Neurol 2011;13:28–40.

55. Probyn K, Bowers H, Mistry D, et al. Non-pharmacological self-management for people living with migraine or tension-type headache: a systematic review including analysis of intervention components BMJ Open 2017;7:e016670.

56. Lemstra M, Stewart B, Olszynski WP. Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. Headache 2002;42:845–54.

57. John PJ, Sharma N, Sharma CM, Kankane A. Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial. Headache 2007;47:654–61.

58. Harris P, Loveman E, Clegg A, et al. Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults Br J Pain 2015;9:213–24.

59. Kropp P, Meyer B, Meyer W, Dresler T. An update on behavioral treatments in migraine - current knowledge and future options. Expert Rev Neurother 2017:1–10.

60. Sullivan A, Cousins S, Ridsdale L. Psychological interventions for migraine: a systematic review. J Neurol 2016;263:2369–77.

61. Holroyd KA, Cottrell CK, O’Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 2010;341:c4871.

62. Penzien DB, Rains JC, Andrasik F. Behavioral management of recurrent headache: three decades of experience and empiricism. Appl Psychophysiol Biofeedback 2002;27:163–81.

63. Smith TR, Nicholson RA, Banks JW. A primary care migraine education program has benefit on headache impact and quality of life: results from the mercy migraine management program. Headache 2010;50:600–12.

64. Rothrock JF, Parada VA, Sims C, et al.The impact of intensive patient education on clinical outcome in a clinic-based migraine population. Headache 2006;46:726–31.

Case Conclusion

Our patient is a young woman with a history of headaches suggestive of migraine without aura. Since her headache frequency ranges from 4-8 headaches month, she has episodic migraines. She also has a strong family history of headaches. She denies any other medical or psychiatric comorbidity. She reports an intake of a caffeine-containing medication of 4 to 15 tablets per month.

The physician recommended that she limit her intake of the caffeine-containing medication to 5 days or less per month given the risk of migraine transformation. The physician also recommended maintaining a good sleep schedule, limiting excessive caffeine intake, a stress reduction program, regular cardiovascular exercise, and avoiding skipping or delaying meals. The patient was educated about migraine and its underlying mechanisms and the benefits of taking medications, and her fears regarding medication use and side effects were allayed. Sumatriptan 100 mg oral tablets were prescribed to be taken at headache onset. She was hesitant to be started on an antihypertensive or antiseizure medication, so she was prescribed amitriptyline 30 mg at night for headache prevention. She was also asked to maintain a headache diary. The patient was agreeable with this plan.

Summary

Migraine is often underdiagnosed and undertreated. Primary care providers are often the first point of contact for these patients. Identifying the type and frequency of migraine and comorbidities is necessary to guide appropriate management in terms of medications and lifestyle modifications. Often no testing or imaging is required. Educating patients about this chronic disease, treatment expectations, and limiting intake of medication is essential.

Corresponding author: Pooja Mohan Rao, MBBS, MD, Georgetown University Hospital, 3800 Reservoir Rd. NW, 7 PHC, Washington, DC 20007, Pooja.Rao@gunet.georgetown.edu.

Financial disclosures: Dr. Ailani reports receiving honoraria for speaking and consulting for Allergan, Avanir, and Eli Lilly.